Context: Regulation of maternal thyroid hormones during pregnancy is crucial for optimal maternal and fetal outcomes. There are no specific guidelines addressing maternal levothyroxine (LT4) dose adjustments throughout pregnancy.
hypothyroidism (3) . ATA suggests repeating thyroid function tests (TFTs) at least every 4 weeks during the first half of pregnancy and again at least once between weeks 26 and 32 (1) . The Endocrine Society (ES) suggests repeating TFTs every 4 to 6 weeks throughout pregnancy (2) and, like ATA, recommends levothyroxine (LT4) dose adjustments to maintain TSH within trimester-specific goal ranges. However, some clinicians advocate for more frequent monitoring of thyroid function to ensure compliance and efficacy of dose adjustments (4) .
Currently, there are no guidelines outlining a specific method for managing the LT4 dose in hypothyroid patients throughout the entire pregnancy. In general, the greatest LT4 dose increases occur in T-1; however, dose adjustments may also be necessary in T-2, with doses typically stabilizing or decreasing in T-3 (5) . That said, there is substantial variability in the number and magnitude of LT4 dose adjustments that are required during individual pregnancies. For example, degree of LT4 dose increase varies with etiology of hypothyroidism: athyreotic women require larger dose increases (approximately 50% increase) compared with women with thyroid cancer (TC) (21% increase) and autoimmune hypothyroidism [Hashimoto disease (HD)] (16% increase) (6) . In a large retrospective study of pregnant hypothyroid women, although most required higher LT4 doses during pregnancy, dose requirements did not change (3.2%) or even decreased (1.9%) in some women. Of the women requiring dose increases, there was variability in the magnitude of change required to maintain goal TSH, due at least in part to different etiologies for hypothyroidism (7) .
Various methods for adjusting LT4 replacement in pregnant hypothyroid women have been suggested and are being used clinically; however, rigorous comparisons of current practice paradigms have not been performed. In an attempt to avoid abnormal maternal TSH levels at any time during pregnancy, some practitioners suggest checking serum TSH every 2 weeks during T-1, and less frequently thereafter, with dose adjustments made on an individual basis to maintain goal TSH (5, 8) . Another proposed method, endorsed by the ATA (1), is to empirically increase the prepregnancy LT4 dose by approximately 30% once pregnancy is confirmed, without first measuring serum TSH (5, 9 ). This method was tested by randomizing hypothyroid pregnant women to increase their LT4 dose by either two or three doses per week as soon as pregnancy was confirmed. This empiric LT4 dose increase was relatively safe and effective at preventing maternal hypothyroidism; however, a significant number of women exhibited TSH ,0.1 mIU/L (17%) or .2.5 mIU/L (31%) at some point during pregnancy (9) . In addition, many women required additional LT4 dose adjustments after the initial two-or three-dose/week increase.
The current study directly compares two distinct algorithms for LT4 dose adjustment during pregnancy in a randomized, prospective trial of women with varying etiologies of hypothyroidism on long-term LT4 replacement therapy.
Materials and Methods
Women aged 18 to 45 years with known hypothyroidism on a stable LT4 dose and #11 weeks of gestation were eligible. Women were referred from endocrinology clinics at MedStar Washington Hospital Center and MedStar Georgetown University Hospital in Washington, DC, where all study visits occurred between October 2011 and December 2015. The joint MedStar Washington Hospital Center/MedStar Georgetown University Hospital Institutional Review Board approved this study. All participants signed Institutional Review Boardapproved informed consent documents after meeting with a study investigator prior to study initiation.
Study inclusion criteria included women aged 18 to 45 years with hypothyroidism, taking a stable dose of LT4 for $2 months, #11 weeks gestation at study entry, documented serum TSH within the normal nonpregnancy reference range #3 months prior to pregnancy, and positive urine or serum b-human chorionic gonadotropin (hCG). Exclusion criteria included treatment with radioactive iodine therapy in the previous 12 months, unwillingness/inability to take a prenatal multivitamin containing 150 mg potassium iodide, use of any T3-containing thyroid replacement medication in the previous 3 months, and TC requiring continuation of suppressive doses of LT4 during pregnancy. Any cause of hypothyroidism that was diagnosed prior to pregnancy was acceptable for study enrollment. Patients with TC were included only if they had stage 1 or 2 (low-risk) disease not requiring TSH-suppressive doses of LT4 during pregnancy; specifically for such patients, recent guidelines suggest maintaining TSH in the lower half of the reference range during pregnancy given that concurrent stimulation from hCG is also present (1) . Subclinical hypothyroidism (SCH) was defined as TSH .4.5 mIU/L and ,10 mIU/L with normal free thyroxine (fT4) levels.
At enrollment, each woman completed a health history questionnaire that included complete medical and surgical history, current medications, history of thyroid dysfunction (including date of diagnosis, previous thyroid surgery or I-131 therapy, current LT4 dose, and most recent prepregnancy TSH), and obstetric history. Questionnaire responses were confirmed by study investigators after review of electronic medical records.
At enrollment, patients underwent baseline laboratory testing for serum TSH, fT4, total T3, anti-thyroid peroxidase antibody (TPO-AB), anti-thyroglobulin antibody (TG-AB), and qualitative b-hCG, followed by random assignment to one of two dose-adjustment groups. TSH, fT4, total T3, and TPO-AB were measured by electrochemiluminescence immunoassay. TG-AB was measured by immunochemiluminometric assay.
Patients in group 1 (G1) increased their LT4 dose empirically by two doses per week above the prepregnancy daily LT4 dose. Thereafter, dose adjustments were made every 2 weeks in T-1 and T-2 and every 4 weeks in T-3 in dose-per-week increments according to the G1 dose-adjustment algorithm (Fig. 1) to maintain serum TSH within trimester-specific goal ranges. In group 2 (G2), dose adjustments were made in m/d increments based on serum TSH and the current LT4 dose according to the G2 dose-adjustment algorithm (Fig. 1) . Similarly to G1, dose adjustments in G2 were made at study entry, every 2 weeks in T-1 and T-2, and every 4 weeks in T-3 to maintain trimesterspecific goal TSH. In both groups, goal TSH was 0.4 to 2.5 mIU/L in T-1 and 0.4 to 3.0 mIU/L in T-2 and T-3. To avoid undermedicating women with suppressed TSH due to high levels of b-hCG in T-1, T-1 TSH ,0.4 mIU/L was considered at goal as long as fT4 remained within normal limits.
The primary outcome measure was the proportion of maternal TSH values within trimester-specific goal ranges in each dose-adjustment group. Secondary outcomes included mean number of LT4 dose adjustments per patient, mean TSH, proportion of TSH values within trimester-specific reference ranges per trimester, mean number of LT4 dose adjustments according to hypothyroidism etiology, and proportion of TSH values within trimester-specific goal ranges according to anti-thyroid antibody status (TPO-AB +/-and/or TG-AB +/-).
Statistical analyses
Each participant was randomized at each pregnancy; therefore, the unit of analysis was each individual pregnancy. Analyses were performed between groups to compare mean TSH, number and proportion of TSH values in trimesterspecific goal ranges, and mean number of LT4 dose adjustments per patient. Comparisons were also stratified by trimester, etiology of hypothyroidism, and antibody status. For continuous variables, including TSH and number of LT4 dose adjustments, Student t tests were used to compare groups. When also including trimester, hypothyroidism etiology, and/or thyroid antibody status as variables, two-way analysis of variance (ANOVA) was used. For categorical variables, x 2 test for independence was used. P , 0.05 was considered significant. All analyses were done using R Foundations for Statistical Computing, version R 3.3 (Vienna, Austria).
Results
A total of 34 women were enrolled during 38 unique pregnancies. Five women were randomized twice during two separate pregnancies. All 38 pregnancies delivered at or near term: gestational age at delivery was 38.7 6 1.9 weeks (mean [6 standard deviation (SD)]) in the overall study population (G1, 38.2 6 1.8 weeks vs G2, 39.4 6 1.8 weeks, P = 0.06). Thirty-five (92%) pregnancies were singleton (G1, n = 18; G2, n = 17), and three (8%) pregnancies were twin gestations (G1, n = 2; G2, n = 1).
Twenty pregnancies were randomized to G1 and 18 to G2. There were no differences in baseline demographic, pregnancy-related, or hypothyroidism-related characteristics between groups (Table 1) . Of the women with Graves disease (GD) enrolled in the study (three women with four pregnancies: in G1, n = 1 pregnancy and in G2, n = 3 pregnancies), all three women had received treatment with radioactive iodine ablation .12 months prior to study entry (range, 19 to 46 months).
At enrollment, TSH was ,2.5 mIU/L in 95% of pregnancies (36 of 38) and TSH was ,0.1 mIU/L in 18% of pregnancies (7 of 38). Of the seven pregnancies with TSH ,0.1 mIU/L at enrollment, six (86%) occurred in women with TC, and one (14%) occurred in a woman with GD. The mean prepregnancy TSH was significantly lower in women with TC compared with women with other hypothyroidism etiologies (TC, 0.3 6 0.3 mIU/L; HD, 1.5 6 1.2 mIU/L; SCH, 1.4 6 0.1 mIU/L; and GD, 1.3 6 1.5 mIU/L; P , 0.001).
Mean age of gestation at enrollment was 6.4 6 2.1 weeks (range, 4 to 11 weeks). Ninety-seven percent of Figure 1 . Dose-adjustment algorithms by study group. doi: 10.1210/jc.2017-01086 https://academic.oup.com/jcempregnancies (37/38) were enrolled by #10 weeks gestation, 89% (33/38) by #8 weeks gestation, and 71% (27/ 38) by #6 weeks gestation. Mean TSH during pregnancy in the overall study population was 1.5 6 1.8 mIU/L. Women in G1 had a lower mean TSH compared with women in G2, primarily due to lower TSH in T-1. In T-2 and T-3, mean TSH was not different between groups ( Table 2 ). The three women with twin pregnancies (participants 6, 16, and 27) did not exhibit greater TSH suppression or require more LT4 dose changes compared with the overall study cohort (Fig. 2) . Mean TSH during the three twin pregnancies was 0.6 6 0.2 mIU/L, 3.1 6 5.0 mIU/L, and 1.1 6 0.9 mIU/L for participant 6, 16, and 27, respectively. Participant 6 required six LT4 dose changes, and participants 16 and 27 each required three dose changes during their respective pregnancies.
For the entire study population, mean number of LT4 dose adjustments per pregnancy (excluding the empiric dose increase in G1) was 3.5 6 2.7 (range, 0 to 7, G1, and 0 to 11, G2). There was no difference in the number of dose adjustments required per pregnancy between G1 and G2 (Table 2) . When the empiric increase in G1 was included, the number of dose adjustments per group was also not different between groups (G1, 4.1 6 2.1 vs G2, 4.1 6 3.2, P = 0.8). In the entire cohort, dose adjustments were most often required in T-2 (58 total dose changes; average, 1.5 per pregnancy), followed by T-3 (41 total dose changes; average, 1.1 per pregnancy) and T-1 (36 total dose adjustments; average, 0.9 per pregnancy). However, including the empiric dose increase in G1 resulted in a total of 56 dose adjustments in T-1 (average, 1.5 per pregnancy).
Seventy-five percent of all TSH values were within trimester-specific goal ranges in G1, compared with 81% in G2 (P = 0.09). In T-1, TSH was more often within the trimester-specific goal range in G2 compared with G1. In T-2 and T-3, there were no differences in the percentages of TSH values within trimesterspecific goal ranges between groups (Table 2) .
During the entire pregnancy and during each trimester, mean TSH did not differ between groups based on hypothyroidism etiology (Table 2) . However, a greater percentage of TSH values were within trimester-specific reference ranges in women with HD and SCH compared with women with GD or TC within each group and in the overall study population. In the overall cohort, 85% of TSH values were within trimester-specific ranges in women with HD, 90% in women with SCH, 74% in women with TC, and 53% in women with GD (P , 0.001). Interestingly, mean number of LT4 dose adjustments was significantly higher in women with TC or GD compared with women with HD or SCH ( Table 2) . Compared with G1, women in G2 achieved higher percentages of TSH within trimester-specific goal ranges across all hypothyroidism etiologies (Table 2 ). There were no consistent between-group differences in the number of LT4 dose adjustments required by hypothyroidism etiology (Table 2) .
Among all pregnancies in G1, 81% (13 of 16) had an initial 2-week postenrollment TSH #2.5 mIU/L and 18% (3 of 16) (participant 4 and participant 13 with HD, participant 33 with GD) had an initial TSH .2.5 mIU/L (2-week postenrollment TSH was missing for four pregnancies in G1) (Fig. 3) . Of the 13 pregnancies in G1 with TSH #2.5 at the 2-week postenrollment check, four women (30%) had TSH ,0.1 mIU/L. Only one woman (participant 35 with TC) in G1 developed a suppressed TSH to ,0.1 mIU/L after empiric LT4 dose increase; her TSH decreased from 0.9 mIU/L (week 4) to 0.09 mIU/L (week 6) and subsequently improved to 1.0 mIU/L (week 10). The other three women in G1 with a 2-week postenrollment TSH ,0.1 mIU/L had TSH values ,0.1 mIU/L on initial laboratory testing, and TSH either improved or remained unchanged after the empiric dose increase. Among participants in G2, 93% (14 of 15) had TSH #2.5 mIU/L at 2-week postenrollment testing, and one woman (7%) (participant 14 with GD) had Figure 2 . TSH values (mIU/L) by pregnancy week and average weekly LT4 doses (mg; red) in the three twin pregnancies. (Fig. 3) . Two-week postenrollment TSH was not suppressed to ,0.1 mIU/L in any G2 participant. The percentages of women with positive TPO-AB, positive TG-AB, and either positive TPO-AB or positive TG-AB were similar between groups (Table 1) . When antibody status was assessed by hypothyroidism etiology, no women with TC, SCH, or GD had positive TPO-AB, compared with seven women (47%) with HD (P = 0.012), and no women with SCH or GD had positive TG-AB, compared with one woman with TC (7%) and six women with HD (46%) (P = 0.06). There was no effect of antibody status on mean TSH in the entire study population or within each group (Table 3) . In both groups and in the entire cohort, TPO-AB+ women had a similar proportion of TSH values within trimester-specific goal ranges compared with TPO-AB-women. Interestingly, in both groups and overall, TG-AB+ women had a significantly higher proportion of TSH values within trimesterspecific goal ranges compared with TG-AB-women, primarily due to a higher proportion of TSH within the trimester-specific goal range in TG-AB+ women compared with TG-AB-women in T-1 (Table 3) .
Discussion
Abnormal maternal thyroid function during pregnancy is known to have multiple deleterious consequences for both maternal and fetal health, including spontaneous miscarriage or fetal death, preterm delivery, gestational hypertension, preeclampsia, placental abruption, postpartum hemorrhage, and neurologic and cognitive impairment to the offspring (10) (11) (12) (13) (14) (15) . Thus precise regulation of maternal thyroid hormone levels during pregnancy is paramount for optimizing pregnancy outcomes. We directly compared two algorithms for LT4 dose adjustment during pregnancy (empiric dose increase followed by ongoing adjustment using a pill-perweek approach vs ongoing adjustment only using a micrograms-per-day approach). We found that the proportion of TSH values within trimester-specific reference ranges was high in the overall study population (78%) and did not statistically differ between pregnancies randomized to G1 compared with G2. That said, in T-1, pregnancies in G2 achieved a higher proportion of TSH values within goal range, primarily due to greater risk of TSH suppression in G1, which used an empiric two-pillper-week dose increase, compared with G2, without an empiric dose increase. Specifically, four women in G1 compared with none in G2 had TSH ,0.1 mIU/L at the 2-week postenrollment check. One of these women in G1 had a twin gestation (participant 16). A higher risk of TSH suppression after empiric dose increase is supported by the significantly lower mean TSH during pregnancy in G1 compared with G2. Not surprisingly, this was primarily due to a significantly lower TSH in G1 in T-1, but not in T-2 or T-3. It is noteworthy that in three of four women in G1 with oversuppressed T-1 TSH, TSH was also suppressed to ,0.1 mIU/L at study enrollment and remained suppressed after the empiric dose increase, suggesting that an empiric dose increase in early pregnancy may not be the best option for women with suppressed prepregnancy TSH (e.g., women with TC maintained on suppressive doses of LT4). In this regard, prepregnancy TSH was significantly lower in women in our cohort with TC compared with women with hypothyroidism due to other etiologies. However, among pregnancies in women with TC, 73% of TSH values were within trimester-specific goal ranges in G1 compared with 75% in G2, suggesting that despite the potential increased risk of TSH oversuppression with the empiric dose increase used in G1, women with TC, who were more likely to have suppressed TSH at the onset of pregnancy, may be well controlled throughout pregnancy using either dose-adjustment algorithm.
Women with GD had the lowest percentage of TSH values within trimester-specific reference ranges, regardless of treatment group, compared with the other etiological subpopulations in our cohort (G1, 45%; G2, 60%; overall, 53%); however, these data are limited by the small size of this subpopulation. Pregnancies in women with SCH had the best overall control of TSH throughout pregnancy compared with other etiological subpopulations (G1, 87%; G2, 100%; overall cohort, 90% of TSH within trimester-specific goal ranges). This perhaps suggests that women with milder forms of nonsurgical hypothyroidism are more easily controlled during pregnancy; again, however, the small size of the SCH subpopulation limits conclusions that can be drawn.
Overall, mean TSH did not differ based on antibody status. Specifically, proportion of TSH values within trimester-specific ranges did not differ based on TPO-AB status. Interestingly, we found that TG-AB+ women had a higher proportion of TSH values within trimester-specific ranges compared TG-AB-women, primarily due to differences in T-1 alone. However, these data are limited by the small number of TG-AB+ pregnancies (G1, n = 3; G2, n = 4). Women with TC and GD required more than twice as many LT4 dose adjustments compared with women with HD or SCH, perhaps due to residual endogenous thyroid function in the latter two groups. Regardless of hypothyroidism etiology, the average number of dose adjustments required per pregnancy was low (mean: 3.5, excluding empiric dose increases; range: G1, 0 to 7; G2, 0 to 11). Dose adjustments were required approximately equally across each trimester of pregnancy. In the overall cohort, after excluding empiric dose increases in G1, 0.9 dose changes per pregnancy were required in T-1, 1.5 in T-2, and 1.1 in T-3. Including the empiric dose increases in G1, 1.5 dose changes per pregnancy were required in T-1. It is noteworthy that LT4 dose adjustments were required throughout pregnancy, rather than primarily in T-1, in contrast to what has generally been reported in the literature (5) . This provides support to guidelines recommending that close TSH monitoring extend during the entirety of pregnancy (1, 2). In our cohort, TSH optimization prior to conception may explain the low number of T-1 dose adjustments required.
The overall low number of LT4 dose adjustments required in our study suggests that less frequent TSH monitoring than we used (every 2 weeks in T-1/T-2 and every 4 weeks in T-3) is likely sufficient for maintaining TSH within trimester-specific goal ranges, especially among women with early pregnancy TSH at goal. Specifically in that regard, our data support current guidelines for TSH monitoring put forth by the ES (2) and the ATA (1), which recommend monitoring TFTs every 4 to 6 weeks throughout pregnancy (ES) and every 4 weeks until midgestation and once again around week 30 (ATA), respectively. That said, in our cohort, the etiology of hypothyroidism was a factor in the number of LT4 dose adjustments required, such that women with TC and GD needed approximately five dose adjustments per pregnancy, compared with women with HD or SCH, for whom only approximately two dose adjustments per pregnancy were required. Additionally, women with TC and GD had a lower proportion of TSH values within trimester-specific ranges compared with women with HD or SCH, suggesting that more vigilant monitoring may be needed in these subpopulations of women to maintain optimal control of maternal thyroid function during pregnancy.
A major strength of our study is that we enrolled participants very early in gestation, when maternal thyroid hormone levels are most essential for fetal development. Mean gestational age at study entry was 6.4 6 2.1 weeks, with 97% of participants enrolled before 10 weeks gestation, 87% before 8 weeks gestation, and 71% before 6 weeks gestation. In addition, our study represented women with multiple etiologies of hypothyroidism, allowing us to explore potential relationships between hypothyroidism etiology and LT4 dose-adjustment requirements. Study limitations include a relatively small number of participants (n = 34 women with 38 unique pregnancies) with excellent control of their thyroid disease at baseline. At enrollment, 95% of study participants had TSH values within the T-1 reference range, suggesting our cohort was overall compliant and motivated. Additionally, subpopulations of pregnancies in women with SCH and GD in our study were small compared with subpopulations with TC and HD, limiting our ability to draw conclusions, specifically in these smaller subpopulations.
In summary, we directly compared two LT4 doseadjustment algorithms in pregnant hypothyroid women and demonstrated that both algorithms maintained maternal TSH within trimester-specific reference ranges for the majority of pregnancy. The two LT4 doseadjustment algorithms we designed thus provide specific, effective options for practitioners caring for pregnant hypothyroid women. Our data support and extend current clinical practice guidelines (1, 2) by providing clinicians with a choice of two practical methods for LT4 dose adjustment during pregnancy. Multiple patient-specific factors, including prepregnancy TSH, etiology of hypothyroidism, and patient preference, may help guide the best choice of algorithm for each pregnant hypothyroid woman.
